Novanta Inc. (NOVT) stock analysis
Technology · Scientific & Technical Instruments
From the 10-K filed 2026-02-23
Business type: Franchise
How it makes money
It earns 53% of revenue by supplying proprietary precision technologies to medical OEMs, where surgical procedure volumes and hospital capital spending drive demand.
The company engineers precision components for long-lived OEM equipment platforms, with medical applications now representing the majority of its business. Profitability is heavily influenced by the product mix and the specific timing of new OEM product launches.
Revenue is tied to the capital expenditure budgets of hospitals and healthcare providers, as well as the overall growth in surgical procedure volumes. The remaining 47% of revenue comes from advanced industrial markets, including microelectronics and robotics.
What protects it: the moat
It relies on proprietary technology expertise and being designed into long life-cycle OEM platforms that are difficult for customers to transition away from.
Management claims a competitive advantage through deep proprietary technology expertise in areas like advanced surgery and robotics. Once its components are integrated into an OEM's product design, the high performance requirements and long platform life-cycles create high switching costs.
By embedding its precision medicine and automation competencies into these multi-year customer platforms, it creates a high-friction environment for competitors attempting to displace its established technical solutions.
What growth costs
It spent €64.8 million on the Keonn acquisition and raised $613.1 million through tangible equity units to fund its technology initiatives.
Expansion is funded through strategic acquisitions like the purchase of Keonn to broaden its RFID capabilities and through significant capital raises, including $613.1 million from tangible equity units.
Continuous reinvestment in research and development is required to maintain its proprietary technical portfolio and to launch application-specific products. It also faces costs related to regionalizing its manufacturing into centers of excellence and deploying lean principles across its production sites.
What could damage it
A cyclical oversupply in the microelectronics or industrial capital equipment sectors can force a sharp decline in the demand for its proprietary technology.
Sudden downturns in the cyclical microelectronics and industrial capital equipment markets can trigger a collapse in demand for the company's precision components. These sectors have historically experienced periods of oversupply that lead to reduced capital investment from its industrial customers.
Earnings are also vulnerable to shifts in government policy, such as reduced budget allocations to agencies like the NIH, which can directly impact the research and development budgets of its life science customers.
About Novanta Inc.
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.